Delivery Order SPE2DB22D2108-SPE2DB25FU5VV
Award Date 9/16/25
Potential Completion Date 9/17/25
Potential Value $36K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency (DLA) awarded a $24,925.53 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on September 18, 2025, with an ultimate completion date of September 19, 2025. This firm fixed-price, competitively awarded contract was placed with no set-aside designation and is being performed at the contractor's facility in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used to treat high cholesterol, and the SureClick...
- The Defense Logistics Agency awarded a delivery order valued at $1,041.42 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of August 5, 2025. This non-competitive, firm fixed-price delivery order was issued on August 4, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used for cholesterol management in patients with cardiovascular...
- The Defense Logistics Agency awarded a delivery order valued at $1,388.56 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of July 23, 2025. This non-set-aside, competitively awarded delivery order utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor used for cholesterol management, and the SureClick auto-injector delivery mechanism...
- The Defense Logistics Agency awarded a $20,623.85 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of July 22, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical distributor,...
- The Defense Logistics Agency awarded a delivery order valued at $32,299.03 to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 8, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed-price pricing and represents a pharmaceutical supply delivery to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,540.44 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 18, 2025. This firm fixed-price delivery order, awarded on September 17, 2025, represents a non-competitive set-aside contract and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a PCSK9 inhibitor prescribed for cholesterol...
- The Defense Logistics Agency awarded a $22,002.23 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injector pens, with an ultimate completion date of October 23, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. REPATHA (evolocumab) is a PCSK9 inhibitor used in cardiovascular disease...
- The Defense Logistics Agency awarded a $2,455.27 delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/mL SureClick auto-injectors. This firm fixed price, non-set-aside contract was awarded on October 23, 2025, with an ultimate completion date of October 24, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $55,794.54 to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on October 29, 2025, with completion scheduled for October 30, 2025. This firm fixed-price delivery order represents a competitively awarded, non-set-aside contract with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $53,478.59 firm fixed price delivery order to AmerisourceBergen Drug Corp for REPATHA 140 mg/ml SureClick auto-injectors on September 2, 2025, with an ultimate completion date of September 3, 2025. This non-set-aside competitive award is being performed at the company's corporate office in Conshohocken, Pennsylvania. REPATHA (evolocumab) is a monoclonal antibody used to treat high cholesterol in patients with cardiovascular disease, and the SureClick...